Nephrocare Health Services Ltd (NEPHROPLUS) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a steady performance in Q1 FY27, with revenue growing over 20% year-on-year, driven by the strength of its platform business model and disciplined execution.
- Strategic expansion continued with the addition of 26 new clinics (19 in India, 7 in the Philippines), extending the network to 550 clinics across 370 cities in 5 countries.
- International operations have become a significant contributor, now accounting for approximately 45% of total revenue, validating the replicability of the "India model" in global markets.
- The company demonstrated strong profitability improvement, with adjusted EBITDA margins expanding by 120 basis points year-on-year, attributed to operating leverage and a higher share of international business.
- Management reiterated its focus on a three-pronged growth strategy: increasing volume in existing clinics, expanding the footprint in current countries, and selectively entering new geographies, providing visibility for long-term sustainable growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.